Avances y líneas de investigación en el tratamiento y diagnóstico del tabaquismo.
- De Granada-Orive, JI.
- De Granada-Beltrán, AM.
- Segrelles-Calvo, G.
- López-Padilla, D.
- Jiménez Ruiz, CA.
- Solano-Reina, S.
ISSN: 1887-8571
Year of publication: 2017
Volume: 73
Issue: 1
Pages: 57-65
Type: Article
More publications in: Sanidad militar: revista de sanidad de las Fuerzas Armadas de España
Abstract
At the present time, the tobacco abstinence rates increase up to 50% with the therapeutic arsenal available, in the best-case scenario. That is why we are in the need for new treatments that achieve higher abstinence rates per year, given that smokers who remain are those with greater dependence. Also, we must give a thorough look into new possibilities for varenicline. There are on-going investigations searching for new therapeutic targets such as agonists and antagonists of GABA and glutamate, acetylcholine receptors, serotonin agonists, selective inhibitors of monoamine oxidase, and noradrenergic agonists. Moreover, the electronic cigarette requires a position at the present time as a treatment for smoking cessation, and other therapeutic approaches like magnetic intracranial stimulation, mindfulness or nicotine vaccine should be explored as well, added to seeking biomarkers in order to obtain higher abstinence with all these combined.